Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Multi-centre phase II trial for new brain tumor surgical technique starts in the UK

A multi-centre phase II clinical trial for a pioneering new surgical technique has started in the UK, jointly funded by Samantha Dickson Brain Tumour Trust and Cancer Research UK.

1 Nov 2011

Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

Circadian Technologies Limited announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug application from the U.S. Food and Drug Administration to initiate clinical trials of VGX-100.

31 Oct 2011

YM BioSciences announces results of nimotuzumab Phase II study on DIPG

YM BioSciences Inc. today announced that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG) were reported at the 43rd Congress of the International Society of Paediatric Oncology (SIOP) conference being held in Auckland, New Zealand.

31 Oct 2011

'Heroes of Hope Race for Brain Tumor Research' event to be held on Nov. 6

Veronica Cappalonga, 28, knows a lot about living with cancer. Diagnosed at age 6 with leukemia and at 22 with a malignant brain tumor, the Los Angeles (Mar Vista area) resident will walk in the Nov. 6 Heroes of Hope Race for Brain Tumor Research - not only to help fundraise, but also to show that survivors can fight these diseases with dignity.

29 Oct 2011

Nestin-driven oncolytic viruses show effectiveness in glioblastoma models

A new fourth-generation oncolytic virus designed to both kill cancer cells and inhibit blood-vessel growth has shown greater effectiveness than earlier versions when tested in animal models of human brain cancer.

28 Oct 2011

Two proteins bind together to ignite and sustain malignant brain tumors

Two previously unassociated proteins known to be overly active in a variety of cancers bind together to ignite and sustain malignant brain tumors, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports this week in the journal Cancer Cell.

22 Oct 2011

Brain tumour discovery offers drug treatment hope

Australian scientists have played a key role in the identification of a new biochemical mechanism that allows brain tumours to survive and grow, offering hope of new drug treatments for some of the most aggressive tumours.

17 Oct 2011

Scientists uncover vast new gene regulatory network linked with cancer

Researchers at Columbia University Medical Center (CUMC) and two other institutions have uncovered a vast new gene regulatory network in mammalian cells that could explain genetic variability in cancer and other diseases.

15 Oct 2011

Nature publishes Sangamo's gene correction strategy for A1AT deficiency

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of a preclinical study demonstrating highly specific, functional correction of the alpha 1-antitrypsin (A1AT) gene defect in patient-derived induced pluripotent stem cells (iPSCs) using zinc finger nucleases.

14 Oct 2011

Scientisits uncover evidence of powerful new cancer genetic networks

In findings with major implications for the genetics of cancer and human health, researchers at Beth Israel Deaconess Medical Center (BIDMC) and two other science teams in New York City and Rome have uncovered evidence of powerful new genetic networks and showed how it may work to drive cancer and normal development.

14 Oct 2011

UCLA's screening system can target stem cells responsible for glioblastoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have developed and used a high-throughput molecular screening approach that identifies and characterizes chemical compounds that can target the stem cells that are responsible for creating deadly brain tumors.

12 Oct 2011

First patient treated with MagForce's NanoTherm therapy for recurrent glioblastoma

Nanostart-holding MagForce AG, a leading medical technology company focusing on nanomedicine in oncology, announced today the treatment of a recurrent glioblastoma patient with the company's NanoTherm therapy.

11 Oct 2011

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Sangamo BioSciences, Inc. today announced that its Phase 2b study (SB-509-901) did not meet its primary or secondary clinical endpoints in subjects with moderate severity diabetic neuropathy (DN) as compared to placebo.

3 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer.

29 Sep 2011

Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.

29 Sep 2011

YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis

YM BioSciences Inc. today announced that it has enrolled the first patients in its multi-center Phase II trial of CYT387 administered twice-daily (BID) for the treatment of myelofibrosis.

28 Sep 2011

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.

27 Sep 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for its 2011 fiscal year, ended June 30, 2011.

23 Sep 2011